Viva BioInnovator

Viva BioInnovator is the dedicated investment and incubation arm of Viva Biotech, a leading Contract Development and Manufacturing Organization (CDMO) based in Shanghai, China. Established to foster innovation within the life sciences sector, Viva BioInnovator leverages its parent company's extensive expertise and state-of-the-art platforms to support early-stage biotech and pharmaceutical companies. Their unique 'equity for service' (EFS) model allows them to provide crucial CDMO services in exchange for equity, alongside traditional cash investments, thereby significantly de-risking and accelerating drug discovery and development for their portfolio companies.

The firm primarily focuses on investing in innovative drug discovery and development projects, spanning various therapeutic areas and modalities, from small molecules to biologics and cell therapies. Viva BioInnovator typically targets companies from the seed stage through Series B rounds, offering not just capital but also access to Viva Biotech's comprehensive R&D capabilities, including target validation, hit identification, lead optimization, and preclinical development. This integrated approach aims to create a synergistic ecosystem where portfolio companies can benefit from reduced R&D costs and accelerated timelines.

Since its inception, Viva BioInnovator has built a substantial portfolio, demonstrating its significant impact on the biotech landscape. As of late 2023, the firm has invested in over 90 companies globally, showcasing a broad reach beyond its Chinese origins. Their total investment commitment, combining both cash and the value of CDMO services, has exceeded US$1 billion, underscoring their substantial financial backing and strategic commitment to fostering groundbreaking scientific advancements. This dual model of capital and service provision positions Viva BioInnovator as a strategic partner rather than just a financial investor, aiming for long-term success of its ventures.